Think about what else needs to be checkpointed
IL-17, IL-23, and thus IL-6
Google these. Because if you checkpoint these cytokines with a drug....you become a treg inhibitor....possibly without the side effects of IPI. New patent pending of my favorite drug....systemic oral RB as a IL-17, IL-23...and thus IL-6 inhibitor. Opens up all gastric and renal cancers that those ILís affect...including colon and pancreatic....along with kidney. Data based on Poetic research.... which was derived from PH-10 psoriasis study by Dr. Kruger on resetting ILís to normal.
Just saying. Keep an eye on this.
I must say....Provectus is under the radar doing this research. They are patent building for the moment. They are possibly doing a alternative to anti-CTLA4 Yervoy drug by BMY in addition to their intralesional PV-10 drug. Watch for it.
And for you scientists in the field...you know where Iím going with this.